336 related articles for article (PubMed ID: 34429342)
1. COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America: From the COViMS Registry.
Newsome SD; Cross AH; Fox RJ; Halper J; Kanellis P; Bebo B; Li D; Cutter GR; Rammohan KW; Salter A
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34429342
[TBL] [Abstract][Full Text] [Related]
2. The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
Sen S; Tuncer A; Ozakbas S; Uzunkopru C; Baba C; Demir S; Beckmann Y; Gumus H; Arslan G; Kilic AK; Altintas A; Yuceyar N; Turan OF; Tutuncu M; Terzi M; Acar P; Bunul SD; Balci BP; Bir LS; Koseoglu M; Mungan S; Gunduz T; Dogan IG; Kotan D; Uygunoglu U; Ekmekci O; Demirkiran M; Kamisli O; Kabay SC; Tamam Y; Omerhoca S; Sevim S; Guler S; Kurtuncu M; Efendi H; Karabudak R; Siva A
Mult Scler Relat Disord; 2022 Feb; 58():103399. PubMed ID: 35216782
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
7. Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.
Rigal J; Ciron J; Lépine Z; Biotti D
Mult Scler Relat Disord; 2020 Jun; 41():102019. PubMed ID: 32151983
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of coronavirus disease 2019 in patients with neuromyelitis optica and associated disorders.
Louapre C; Maillart E; Papeix C; Zeidan S; Biotti D; Lepine Z; Wahab A; Zedet M; Labauge P; Tilikete C; Pique J; Tourbah A; Mathey G; Dimitri Boulos D; Branger P; Kremer LD; Marignier R; Collongues N; De Seze J
Eur J Neurol; 2021 Oct; 28(10):3461-3466. PubMed ID: 33103295
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD.
Kim S; Seok HY
Neurol Sci; 2023 Jun; 44(6):1841-1848. PubMed ID: 36781562
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
[TBL] [Abstract][Full Text] [Related]
11. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
[TBL] [Abstract][Full Text] [Related]
12. Chiasmatic lesions on conventional magnetic resonance imaging during the first event of optic neuritis in patients with neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein-associated disease in a Latin American cohort.
Carnero Contentti E; López PA; Criniti J; Pettinicchi JP; Cristiano E; Patrucco L; Bribiesca Contreras E; Gómez-Figueroa E; Flores-Rivera J; Correa-Díaz EP; Toral Granda AM; Ortiz Yepez MA; Gualotuña Pachacama WA; Piedra Andrade JS; Galleguillos L; Tkachuk V; Nadur D; Daccach Marques V; Soto de Castillo I; Casas M; Cohen L; Alonso R; Caride A; Lana-Peixoto M; Rojas JI
Eur J Neurol; 2022 Mar; 29(3):802-809. PubMed ID: 34799965
[TBL] [Abstract][Full Text] [Related]
13. Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.
Fan S; Xu Y; Ren H; Guan H; Feng F; Gao X; Ding D; Fang F; Shan G; Guan T; Zhang Y; Dai Y; Yao M; Peng B; Zhu Y; Cui L
Mult Scler Relat Disord; 2018 Feb; 20():144-152. PubMed ID: 29414288
[TBL] [Abstract][Full Text] [Related]
14. Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33411674
[TBL] [Abstract][Full Text] [Related]
15. Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study.
Hümmert MW; Bütow F; Tkachenko D; Ayzenberg I; Pakeerathan T; Hellwig K; Klotz L; Häußler V; Stellmann JP; Warnke C; Goereci Y; Etgen T; Luessi F; Bronzlik P; Gingele S; Lauenstein AS; Kleiter I; Rommer PS; Paul F; Bellmann-Strobl J; Duchow A; Then Bergh F; Pul R; Walter A; Pellkofer H; Kümpfel T; Pompsch M; Kraemer M; Albrecht P; Aktas O; Ringelstein M; Senel M; Giglhuber K; Berthele A; Jarius S; Wildemann B; Trebst C;
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36693760
[TBL] [Abstract][Full Text] [Related]
16. Sex and gender differences in autoimmune demyelinating CNS disorders: Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin-oligodendrocyte-glycoprotein antibody associated disorder (MOGAD).
Diem L; Hammer H; Hoepner R; Pistor M; Remlinger J; Salmen A
Int Rev Neurobiol; 2022; 164():129-178. PubMed ID: 36038203
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
[TBL] [Abstract][Full Text] [Related]
18. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and COVID-19: A Systematic Review.
Mirmosayyeb O; Ghaffary EM; Dehghan MS; Ghoshouni H; Bagherieh S; Barzegar M; Shaygannejad V
J Cent Nerv Syst Dis; 2023; 15():11795735231167869. PubMed ID: 37008248
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.
Yeo T; Siew RWE; Gulam MY; Tye JSN; Aw AYY; Sivalingam T; Peng X; Yong KP; Saffari SE; Chao Y; Tan K
J Neurol; 2023 Jun; 270(6):2817-2825. PubMed ID: 37027019
[TBL] [Abstract][Full Text] [Related]
20. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH
JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
